Skip to main content

Table 1 Baseline characteristics of 1502 HCC patients and patients with high and low FAR risk groups

From: Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

Variables

Total (n = 1502)

Low FAR

(n = 1126)

High FAR

(n = 376)

P value

Age(years)

50 (43, 59)

50 (42, 59)

52 (45, 60)

0.017

Sex

   

0.242

Male

1291 (86.0)

961 (85.3)

330 (87.8)

 

Female

211 (14.0)

165 (14.7)

46 (12.2)

 

Positive HBsAg

1297 (86.4)

979 (86.9)

318(84.6)

0.246

Positive anti-HCV

22 (1.5)

18 (1.6)

4 (1.1)

0.455

Platelet count (109/L)

207 (160, 266)

192 (149, 243)

263 (211, 336)

 < 0.001

Neutrophil count (109/L)

3.6 (2.8, 4.8)

3.3 (2.6, 4.4)

4.5 (3.6, 5.9)

 < 0.001

Lymphocyte count (109/L)

1.7 (1.4, 2.2)

1.8 (1.4, 2.2)

1.7 (1.3, 2.1)

 < 0.001

Monocyte count (109/L)

0.5 (0.4, 0.6)

0.4 (0.3, 0.6)

0.6 (0.4, 0.8)

 < 0.001

Total bilirubin (μmol/L)

13.1 (9.7, 17.9)

13.2 (9.9, 17.8)

12.8 (9.4, 18.2)

0.615

Albumin (g/L)

39.4 (36.2, 42.4)

40.3 (37.4, 43.3)

35.9 (33.5, 39.2)

 < 0.001

ALT (U/L)

35 (24, 50)

35 (24, 50)

34 (22, 54)

0.813

AST (U/L)

39 (29, 57)

37 (29, 54)

46 (32, 69)

 < 0.001

Prothrombin time (s)

12.8 (12.0, 13.6)

12.7 (12.0, 13.6)

12.9 (12.2, 13.9)

0.106

Fibrinogen (g/L)

2.7 (2.2, 3.4)

2.5 (2.1, 2.9)

4.0 (3.5, 4.7)

 < 0.001

Child–Pugh grade

   

 < 0.001

A

1401 (93.3)

1076 (95.6)

325 (86.4)

 

B

101 (6.7)

50 (4.4)

51 (13.6)

 

AFP ( ng/mL)

   

0.449

 ≥ 400

638 (42.5)

472 (41.9)

166 (44.1)

 

 < 400

864 (57.5)

654 (58.1)

210 (55.9)

 

FAR

6.9 (5.5, 8.9)

6.2 (5.2, 7.3)

10.9 (9.6, 13.1)

 < 0.001

NLR

2.1 (1.5, 3.0)

1.9 (1.4, 2.5)

2.9 (2.0, 4.1)

 < 0.001

PLR

115.7 (85.4, 160.6)

104.6 (79.5, 141.7)

157.0 (116.3, 210.5)

 < 0.001

MLR

0.3 (0.2, 0.4)

0.2 (0.2, 0.3)

0.3 (0.3, 0.5)

 < 0.001

SII

422 (262, 682)

354 (229, 543)

744 (485, 1156)

 < 0.001

CSPH

136 (9.1)

111 (9.9)

25 (6.6)

0.060

Ascites

169 (11.3)

106 (9.4)

63 (16.8)

 < 0.001

Cirrhosis

680 (45.3)

527 (46.8)

153 (40.7)

0.039

Tumour size

   

 < 0.001

 > 5

883 (58.8)

570 (50.6)

313 (83.2)

 

 ≤ 5

619 (41.2)

556 (49.4)

63 (16.8)

 

Tumour number

   

0.035

Multiple

288 (19.2)

202 (17.9)

86 (29.9)

 

Single

1214 (80.8)

924 (82.1)

290 (77.1)

 

MVI

393 (26.2)

241 (21.4)

152 (38.7)

 < 0.001

BCLC stage

   

 < 0.001

0

53 (3.5)

51 (4.5)

2 (0.5)

 

A

785 (52.3)

633 (56.2)

152 (40.4)

 

B

257 (17.1)

192 (17.1)

65 (17.3)

 

C

407 (27.1)

250(22.2)

157 (41.8)

 

Blood loss (mL)

   

 < 0.001

 ≥ 400

541 (36.0)

366 (32.5)

175 (46.5)

 

 < 400

961 (64.0)

760 (67.5)

201 (53.5)

 

Blood transfusion

198 (13.2)

123 (10.9)

75 (19.9)

 < 0.001

Extent of resection

   

 < 0.001

Major hepatectomy

754 (50.2)

513 (45.6)

241 (64.1)

 

Minor hepatectomy

748 (49.8)

613 (54.4)

135 (35.9)

 
  1. Continuous data are show as median (25th–75th interquartile range) and categorical data are expressed as n (%)
  2. HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ALT, Alanine aminotransferase; AFP, alpha-fetoprotein; FAR, fibrinogen-albumin ratio; NLR, neutrophil–lymphocyte ratio; MLR, monocyte-lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune–inflammation index; CSPH, clinically significant portal hypertension; MVI, macrovascular invasion; BCLC, Barcelona Clinical Liver Cancer
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us